Image credit: Canva
Researchers are using T-cell therapy to treat certain types of cancer. A clinical trial led by Scott M. Norberg, D.O., Assistant Research Physician in the Center for Immuno-Oncology, is researching T-cell receptor gene therapy targeting KK-LC-1, a cancer germline antigen that is expressed by certain cancers. This therapy may be applicable for epithelial cancers that start in the cells that line an organ. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Monica E. Epstein, R.N., at (240) 281-4207 or monica.epstein@nih.gov
Clinicaltrials.gov identifier: NCT05035407
NCI Protocol ID: 000045
Official Title: A Phase I Trial of T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
